Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) CEO Ajan Reginald discussed the company’s proposed sale of subsidiary Lyramid to Pleiades Pharma with Proactive’s Stephen Gunnion. Reginald explained that the sale, valued at a minimum of $10 million in cash and equity, marks the first step in Roquefort’s transformational strategy for 2025. He described it as a significant return on investment, as the company initially acquired Lyramid for £1 million in 2021.
Pleiades Pharma, led by Caroline Fortier, has a strong track record of successful exits, amounting to $750 million in the past decade. Reginald highlighted that the deal also validates Roquefort’s value creation model and underscores its current market undervaluation. The sale represents one and a half times Roquefort’s market capitalisation, showcasing the company’s ability to acquire, develop, and monetise high-value assets.
“We believe the upside potential with Pleiades Pharma is significant,” Reginald stated, noting Pleiades’ focus on building and exiting clinical asset portfolios. He also hinted …